Older HER2 positive breast cancer
patient showing a patological complete
response to chemo-antiHER2
treatment. A case report.
A. Di Mari, S. Rametta Giuliano, G. Buccafusca, F. Romano, S. Sava, F. Cappuccio, A. Rizzo, K. Coletta, G. Conti, S. Bordonaro
Vol.5 (2020), issue 1, pag. 20 - 26
| Received | 20/03/2020 |
| Accepted | 22/04/2020 |
| Published | 16/06/2020 |
| Review by | Single-blind |
ABSTRACT
Neoadjuvant treatment with a sequential combination of chemotherapy and HER2-targeted therapy is the standard of care for early-stage
HER2-positive breast cancer. The neoadjuvant setting helps to downstage
locally advanced tumors, provides early information about tumor responsiveness, and allows clinicians to assess the efficacy of new therapies in
vivo as well as introduce new targeted therapies into the clinical routine.
Here, we report the case of a patient with advanced HER2-positive breast
cancer who was successfully treated with a combination of chemotherapy
and anti-HER2 agents and ultimately achieved a pathological complete
response. The pathological complete response is a good prognostic indicator of long-term outcome including survival and disease-free survival
in these patients. Our findings support the utility of chemo-anti-HER2
sequential treatment in patients with HER2-positive breast cancer.